Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 11/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737689 | 0.91 | ADK (0.49) | ADKDOT1LPRMT5WDR77ADORA2A | |
| SCHEMBL19859697 | 0.88 | ADK (0.39) | ADKPRMT5WDR77 | |
| SCHEMBL19859748 | 0.86 | ADK (0.51) | ADKDOT1LPRMT5WDR77ADORA2A | |
| SCHEMBL21078598 | 0.81 | P2RX1 (0.47) | — | |
| SCHEMBL1737291 | 0.81 | ADK (0.52) | ADKDOT1LADORA2A | |
| SCHEMBL21078672 | 0.81 | ADK (0.49) | ADKDOT1LPRMT5WDR77ADORA2A | |
| SCHEMBL1735824 | 0.79 | ADK (0.65) | ADKDOT1LPRMT5WDR77ADORA2A | |
| SCHEMBL4428509 | 0.79 | ADK (0.65) | ADKDOT1LPRMT5WDR77ADORA2A | |
| SCHEMBL3229541 | 0.79 | ADK (0.49) | ADKDOT1LPRMT5ADORA2A | |
| SCHEMBL1736097 | 0.79 | ADK (0.44) | ADKDOT1LADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ADK 87/4885DOT1L 3427/4885PRMT5 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.